#mcspc search results
Dr. Elias Chandran @EliasChandran presents unique data re: #immune changes after #docteaxel in #mCSPC #ProstateCancer @asco #GU23 today! Poster #F8 This data may highlight a better path forward for #Immunotherapy in Prostate Cancer. #NKcells meetings.asco.org/abstracts-pres…
📢Darolutamide FDA-approved for de novo mCSPC Prostate Cancer on 6/3/25! ✅10-yr timeline: 2015 (Docetaxel HR 0.73) → 2025 (Darolutamide OS HR 0.81). 📉rPFS HR 0.54. Trial populations matter! 📰In-Depth Article: oncologytube.com/darolutamide-f… #mCSPC #FDAApproval #OncoTwitter…
@cityofhope @TDorffOnc excellent discussant session w/an eye towards future personalized and molecular-guided #mCSPC systemic therapy landscape and de-escalation of ADT + ARPI if PSA nadir <0.2 after 1 yr ARPI @ASCO #GU25 @OncoAlert
Kicking off the #ASCO23 #prostate oral session PEACE-1 results by @AlbertoBossial RT in low volume de novo #mCSPC improves rPFS and CRPS-free survival and prevents serious GU events. Is is time for a "quadruplet" in high burden mCSPC?
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
ADT alone is not enough, upfront combo is needed for all patients with #mCSPC. Data shown in this #AUA2023 session were US + Japanese data (pics attached). European data seem slightly better (also for urologists) but there is clear room for improvement for evidence-based medicine
Improvements in OS regardless of volume status in #mCSPC #ProstateCancer treated w/ #darolutamide and #docteaxel vs. chemo but worth asking if there is sufficient statistical power here to escalate therapy in patients with low volume disease where chemo is now out of favor. #GU23
Clear from #EMBARK @NEJM #BCR not🚫just #mCSPC #ProstateCancer when you do #PSMA PET🩻 ✴️A 5 yr MFS of 70-90% in EMBARK very different than 4-5 yr median OS in mCSPC Data from PRE-Abi/Enza era shows median OS for BCR was 9+ yrs 🚨BCR=more indolent biology should be tx as such
@AlanBryce9 PhIII TRITON3 #PARPi rucaparib superior rPFS vs IC (doce or 2nd-gen ARSI) in chemo-naive #mCRPC (1 prior ARSI & prior chemo allowed in #mCSPC) in #BRCA (64% BRCA2) but not #ATM mt , interim OS 24 vs 20 mos (54% mature in BRCA), 75% crossover @OncoAlert @ASCO #GU23
PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 @OncoAlert
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive #mCSPC #ProstateCancer Interesting data from @neerajaiims & colleagues now published @JUrology auajournals.org/doi/epdf/10.10…
At #GU24, @WallisCJD highlighted his population-based research on treatment intensification shortcomings in de novo #mCSPC. Learn more: buff.ly/3SHPW08
@JosephBBlack work @AmerUrological #AUA2023 assessing prescription patterns for management of #mCSPC with lots of interest from the audience.
Maha Hussain summarizing doublet/triplet treatment for #mCSPC based on #TITAN #ENZAMET #ARASENS #PEACE1. Which patients benefit most from triplet T suppression+NHT+docetaxel? Based on #ENZAMET mainly synch HV. Interesting to see responses to questions asked #AUA2023
Just in👉bit.ly/3AMRBec Real world claims analysis of 10 AEs in #mCSPC. AE rates⬆️over time across Rx groups. Most AE rates with ADT+ARPIs were comparable to ADT+NSAA & ADT alone. ADT+docetaxel had⬆️rates of 7 AEs. Sexual function AE didn't differ between Rx. @OncoAlert
Role of prostate irradiation in de novo low-volume #mCSPC? New SOC “Quadruplet Txt”? ➡️Updated results of #PEACE1: Ph3 trial @AlbertoBossial @GustaveRoussy Intensified txt improved: ✅rPFS ✅CRPC free-survival ❌No impact of RT on OS Minimal added toxicity #ASCO23 @OncoAlert
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
Apalutamide vs Enzalutamide: Racial Disparities in #mCSPC Treatment Outcomes. @UroDrBen @ChesUrology joins @zklaassen_md @GACancerCenter to discuss real-world outcomes comparing apalutamide vs enzalutamide in Black patients with metastatic hormone-sensitive #ProstateCancer.…
The AMPLITUDE results with niraparib/AAP could redefine treatment for HRR-altered mCSPC - impressive rPFS gains with manageable safety. #pcsm #mCSPC
WATCH: Biren Saraiya, MD, provides background on the phase 3 AMPLITUDE study evaluating niraparib + abiraterone acetate in metastatic castration-sensitive prostate cancer. #pcsm #mCSPC hubs.li/Q03v36DF0
#ASCO25 News: FDA approves darolutamide for metastatic castration-sensitive prostate cancer based on ARANOTE trial. Median rPFS not reached—HR 0.54 (P <.0001). bit.ly/3HEoo8J #ProstateCancer #mCSPC @TGAgovau @GovCanHealth @Swissmedic_ @MHRAgovuk
#ASCO25 #mCSPC News: Study #AMPLITUDE: Niraparib + AAP cut radiographic progression risk by 48% in BRCA-mutated metastatic castration-sensitive prostate cancer. A potential new standard? bit.ly/3ZRFB4R #ProstateCancer @uclcancer @quimmateo
oncologynewscentral.com
Is Niraparib Combo the New Standard for Certain Prostate Cancers
Niraparib with abiraterone acetate plus prednisone reduces the risk for radiographic progression for some patients with metastatic prostate cancer, phase 3 data show.
Could earlier genomic testing be the key to better prostate cancer treatment? Gerhardt Attard presents the updates from #ASCO25 you need to know, including a new approach in #mCSPC that can significantly reduce disease progression #MedX #Oncology ow.ly/4Xmb50Wa5eX
In BCR: Apalutamide/Darolutamide. Fit & high-risk: PEACE-1 → Darolutamide triplet. Visceral mets: Abiraterone for rapid cytoreduction. Elderly/frail: Darolutamide for CNS safety. So… where does Enzalutamide truly belong? #ProstateCancer #mCSPC #Oncology
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
📢Darolutamide FDA-approved for de novo mCSPC Prostate Cancer on 6/3/25! ✅10-yr timeline: 2015 (Docetaxel HR 0.73) → 2025 (Darolutamide OS HR 0.81). 📉rPFS HR 0.54. Trial populations matter! 📰In-Depth Article: oncologytube.com/darolutamide-f… #mCSPC #FDAApproval #OncoTwitter…
#ASCO25 #mCSPC News: Study #AMPLITUDE: Niraparib + AAP cut radiographic progression risk by 48% in BRCA-mutated metastatic castration-sensitive prostate cancer. A potential new standard? bit.ly/3ZRFB4R #ProstateCancer @uclcancer @quimmateo
oncologynewscentral.com
Is Niraparib Combo the New Standard for Certain Prostate Cancers
Niraparib with abiraterone acetate plus prednisone reduces the risk for radiographic progression for some patients with metastatic prostate cancer, phase 3 data show.
Niraparib Combo Lowers Progression Risk in HRR-Altered #mCSPC | #ASCO25 hubs.li/Q03qxMpW0
#ASCO25 News: FDA approves darolutamide for metastatic castration-sensitive prostate cancer based on ARANOTE trial. Median rPFS not reached—HR 0.54 (P <.0001). bit.ly/3HEoo8J #ProstateCancer #mCSPC @TGAgovau @GovCanHealth @Swissmedic_ @MHRAgovuk
🚨 @FDA approves #Darolutamide Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬 Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA #ReadNow details on…
🚨BREAKING: The #FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. #mCSPC #pcsm urologytimes.com/view/fda-appro…
BREAKING: The #FDA has approved darolutamide (Nubeqa) for the treatment of metastatic castration-sensitive prostate cancer. #pcsm #mCSPC hubs.li/Q03qwnWy0
Dr. Elias Chandran @EliasChandran presents unique data re: #immune changes after #docteaxel in #mCSPC #ProstateCancer @asco #GU23 today! Poster #F8 This data may highlight a better path forward for #Immunotherapy in Prostate Cancer. #NKcells meetings.asco.org/abstracts-pres…
@AlanBryce9 PhIII TRITON3 #PARPi rucaparib superior rPFS vs IC (doce or 2nd-gen ARSI) in chemo-naive #mCRPC (1 prior ARSI & prior chemo allowed in #mCSPC) in #BRCA (64% BRCA2) but not #ATM mt , interim OS 24 vs 20 mos (54% mature in BRCA), 75% crossover @OncoAlert @ASCO #GU23
Locations of metastases in and oncological outcomes of patients with #mCSPC: Real-world data from a multicenter study. Not all visceral mets are equal in #ProstateCancer. New multicenter mCSPC study shows patients with lung-only metastases have better outcomes than those with…
@cityofhope @TDorffOnc excellent discussant session w/an eye towards future personalized and molecular-guided #mCSPC systemic therapy landscape and de-escalation of ADT + ARPI if PSA nadir <0.2 after 1 yr ARPI @ASCO #GU25 @OncoAlert
@JosephBBlack work @AmerUrological #AUA2023 assessing prescription patterns for management of #mCSPC with lots of interest from the audience.
Kicking off the #ASCO23 #prostate oral session PEACE-1 results by @AlbertoBossial RT in low volume de novo #mCSPC improves rPFS and CRPS-free survival and prevents serious GU events. Is is time for a "quadruplet" in high burden mCSPC?
One of the takeaway slides from this #GU25 about current an future managemnt of #mCSPC from a terrific presentation by @TDorffOnc. @OncoAlert @oncodaily @urofocus @GUOncologyNow
Clear from #EMBARK @NEJM #BCR not🚫just #mCSPC #ProstateCancer when you do #PSMA PET🩻 ✴️A 5 yr MFS of 70-90% in EMBARK very different than 4-5 yr median OS in mCSPC Data from PRE-Abi/Enza era shows median OS for BCR was 9+ yrs 🚨BCR=more indolent biology should be tx as such
ADT alone is not enough, upfront combo is needed for all patients with #mCSPC. Data shown in this #AUA2023 session were US + Japanese data (pics attached). European data seem slightly better (also for urologists) but there is clear room for improvement for evidence-based medicine
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive #mCSPC #ProstateCancer Interesting data from @neerajaiims & colleagues now published @JUrology auajournals.org/doi/epdf/10.10…
🧬 @AttardLab explores integrating biology in #mCSPC at #ESMO23. His insights have always been invaluable, and we look forward to his contribution at #APCCC24. #CancerBiology
Barriers to and facilitators of 1st-line treatment intensification in #mCSPC by practice setting and intensification frequency: A sub-analysis of #IMPLEMENT Why is 1L treatment intensification underused in #mCSPC? A sub-analysis of IMPLEMENT highlights key barriers (knowledge…
PhII rand Metacure trial of oligo #mCSPC SBRT to all mets + ADT + apa +/- abi ➡️ PSA0 w/T recovery (primary endpt) met with 42% with short ADT + apa and 50% w/short course ADT + apa and combined group with abi #ASCO25 @OncoAlert
Real-world comparison of time-to-next-treatment, time-to-castration-resistance, and OS among patients with BRCA1/2 positive and HRR negative #mCSPC. Presentation by @heatherhcheng @fredhutch. #GU25 written coverage by @chavarriagaj @UofT > bit.ly/4b1JIj6 @ASCO
🚨 @FDA approves #Darolutamide Darolutamide (#Nubeqa) is now approved for metastatic castration-sensitive prostate cancer #mCSPC as monotherapy! 🧬 Approval backed by data from the #ARANOTE trial showing significant rPFS benefit. #ProstateCancer #GUonc #FDA #ReadNow details on…
@neerajaiims insights and review in #mCSPC #prostatecancer at #Nextfrontierstocurecancer2023 Always brilliant ! @acccancercenter @StenioZequi @AldoLADETTINO
@charlesryanmd CEO @PCFnews thought-provoking talk on #mCSPC #mCRPC one of the few tumors where we can treat w/hormones, chemo, radioligands, immunotherapy, targeted therapy but disparities remain in how we deliver them to all our pts 2nd Annual @CSCancerCenter #GU onc retreat
Just in👉bit.ly/3AMRBec Real world claims analysis of 10 AEs in #mCSPC. AE rates⬆️over time across Rx groups. Most AE rates with ADT+ARPIs were comparable to ADT+NSAA & ADT alone. ADT+docetaxel had⬆️rates of 7 AEs. Sexual function AE didn't differ between Rx. @OncoAlert
Something went wrong.
Something went wrong.
United States Trends
- 1. Chiefs 71.7K posts
- 2. LaPorta 9,043 posts
- 3. #TNABoundForGlory 33.9K posts
- 4. Goff 11.3K posts
- 5. Butker 7,439 posts
- 6. Kelce 12.2K posts
- 7. #OnePride 5,291 posts
- 8. #DETvsKC 3,631 posts
- 9. Bryce Miller 2,564 posts
- 10. Baker 49.6K posts
- 11. #SNFonNBC N/A
- 12. Collinsworth 1,953 posts
- 13. Gibbs 5,092 posts
- 14. Dan Campbell 2,049 posts
- 15. #ALCS 8,025 posts
- 16. Polanco 6,170 posts
- 17. Pacheco 4,396 posts
- 18. Patrick Mahomes 6,451 posts
- 19. Leon Slater 2,530 posts
- 20. Cal Raleigh 4,557 posts